Samsung Biologics
207940.KS · Bio
World's largest contract biologics manufacturer (CDMO). Produces biosimilars and biologics for global pharma.
Latest news
Songdo Opens Bio Training Center to Ease Talent Shortage
Samsung Biologics Clears Regulator Review of $2.2 Billion Rights Offering
POSCO Technical University Shifts to AI-Focused Curriculum
Samsung Biologics Wins 350.8 Billion Won CMO Deal With European Drugmaker
Samsung Biologics Raises 3 Trillion Won to Enter Peptide CDMO Market
Moderna Moves Beyond Personalized Cancer Vaccines to Universal Shot
China's WuXi Biologics Files 3 Times More INDs Than Korean Rivals
Korea Imports 95% of Biomanufacturing Materials Amid FDA Hurdles
Korea Leads Biologics Capacity but Has No Blockbuster Drug
Medipost Recruits Former Samsung Biologics Executive to Lead Global Push
Samsung Biologics Union, Management to Resume Wage Talks Sept. 8
Samsung Biologics Launches $1.9 Billion Tender Offer for PolyPeptide
Samsung Biologics Cut to 1.85 Million Won as 3 Trillion Won Share Sale Dilutes EPS
Venezuela Weighs OPEC Exit, May Lease Key Oilfields to U.S. for 100 Years
Samsung Biologics Seeks 3 Trillion Won Share Sale for Peptide Push
Samsung Biologics Announces 3 Trillion Won Rights Offering
Samsung Biologics Shares Fall 4% on 3 Trillion Won Share Sale
Samsung Biologics Falls 6% in Premarket After 3 Trillion Won Share Sale
Samsung Biologics to Raise 3 Trillion Won for PolyPeptide Deal
Rznomics Joins Lilly Gateway Labs in San Diego
Samsung Electro-Mechanics Tops Shareholder Returns at 755%; LG Energy, Samsung Biologics Post Losses
Samsung Biologics Jumps 5% Premarket as Moderna Soars 177%
